These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10835875)

  • 21. [Why do patients with kidney diseases end up with a heart of stone? Disturbances in calcium-phosphate balance and chronic inflammation important causes].
    Martola L; Elinder CG; Stenvinkel P
    Lakartidningen; 2003 Dec; 100(50):4180-3. PubMed ID: 14717005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Haemodialysis and hypertension].
    van der Giet M; Zidek W
    Dtsch Med Wochenschr; 2006 Nov; 131(46):2605-9. PubMed ID: 17096308
    [No Abstract]   [Full Text] [Related]  

  • 23. Chronic kidney disease as a cardiovascular risk factor.
    Best PJ; Holmes DR
    Am Heart J; 2003 Mar; 145(3):383-6. PubMed ID: 12660658
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of dialysis modality (PD and HD) on cardiac morphology and functions in chronic kidney disease patients at very high cardiovascular risk.
    Krajewska M; Kosmala W; Weyde W; Madziarska K; Porazko T; Kopec W; Klak R; Penar J; Kusztal M; Watorek E; Golebiowski T; Klinger M
    Nephrol Dial Transplant; 2008 Feb; 23(2):768-9. PubMed ID: 18029367
    [No Abstract]   [Full Text] [Related]  

  • 25. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
    Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ
    Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sleep apnea and daytime sleepiness in end-stage renal disease.
    Hanly P
    Semin Dial; 2004; 17(2):109-14. PubMed ID: 15043611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients.
    Avci E; Coskun S; Cakir E; Kurt Y; Ozgur Akgul E; Bilgi C
    Ren Fail; 2008; 30(8):784-90. PubMed ID: 18791952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality.
    Matsubara K; Suliman ME; Qureshi AR; Axelsson J; Martola L; Heimbürger O; Barany P; Stenvinkel P; Lindholm B
    Blood Purif; 2008; 26(3):284-90. PubMed ID: 18421213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors and underlying cardiovascular diseases in incident ESRD patients.
    Di Benedetto A; Marcelli D; D'Andrea A; Cice G; D'Isa S; Cappabianca F; Pacchiano G; D'Amato R; Oggero AR; Bonanno D; Pergamo O; Calabrò R
    J Nephrol; 2005; 18(5):592-8. PubMed ID: 16299687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cardiovascular disorders in chronic renal failure].
    Bagriĭ AE
    Ter Arkh; 1998; 70(11):80-3. PubMed ID: 9949472
    [No Abstract]   [Full Text] [Related]  

  • 31. Anemia and cardiovascular risk in the patient with kidney disease.
    Fishbane S
    Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardiovascular risk factors in chronic renal failure].
    López Gómez JM; Jofré R; Cases A
    Nefrologia; 2002; 22 Suppl 1():59-67. PubMed ID: 11987672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroke in ESRD: the other cardiovascular disease.
    Seliger SL
    Am J Kidney Dis; 2009 Sep; 54(3):403-5. PubMed ID: 19700060
    [No Abstract]   [Full Text] [Related]  

  • 34. Emerging cardiovascular risk factors in end-stage renal disease.
    Yaqoob MM
    J Nephrol; 2002; 15(2):205-8. PubMed ID: 12018642
    [No Abstract]   [Full Text] [Related]  

  • 35. NKF task force develops recommendations to help reduce CVD mortality in ESRD patients.
    Nephrol News Issues; 1998 Jun; 12(6):41, 45. PubMed ID: 9697477
    [No Abstract]   [Full Text] [Related]  

  • 36. Inadequate treatment of cardiovascular disease and cardiovascular disease risk factors in dialysis patients: a commentary.
    Culleton BF; Hemmelgarn B
    Semin Dial; 2004; 17(5):342-5. PubMed ID: 15461738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of cardiovascular risk during substitution management: silent cardiopathies].
    Machecourt J
    Nephrologie; 2000; 21(7):351-2. PubMed ID: 11200609
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study.
    Kessler M; Zannad F; Lehert P; Grünfeld JP; Thuilliez C; Leizorovicz A; Lechat P;
    Nephrol Dial Transplant; 2007 Dec; 22(12):3573-9. PubMed ID: 17611249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic kidney disease and cardiovascular disease--using the ANNA Standards and Practice Guidelines to improve care. Part 1: the epidemiology of chronic kidney disease: the risk factors and complications that contribute to cardiovascular disease.
    McCarley PB; Burrows-Hudson S
    Nephrol Nurs J; 2006; 33(6):666-74; quiz 675-6. PubMed ID: 17219728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies for improving long-term survival in patients with ESRD.
    Nolan CR
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S120-7. PubMed ID: 16251247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.